Orchestra BioMed Holdings, Inc.


7 (USD) • At close May 29, 2024
Bedrijfsnaam Orchestra BioMed Holdings, Inc.
Symbool OBIO
Munteenheid USD
Prijs 7
Beurswaarde 250,519,500
Dividendpercentage 0%
52-weken bereik 4.22 - 17.35
Industrie Biotechnology
Sector Healthcare
CEO Mr. David P. Hochman
Website https://orchestrabiomed.com

An error occurred while fetching data.

Over Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical

Vergelijkbare Aandelen

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)